Humshaugh & Wark Medical Group

econsult logo - want advice from your doctor, self-help information or have an administrative request (such as a sick note of test results)?
NHS App

Do more with the NHS App. Order repeat prescriptions, book appointments, view your record and much more...

Health A to Z

Find out about conditions, symptoms and treatments, including what to do and when to get help

Medicines A to Z

Find out how your medicine works, how and when to take it, and possible side effects

Obesity Injections, Tirzepatide (Mounjaro)

A pathway is being developed in our ICB area (North East and North Cumbria) for the delivery of weight loss injections. We currently do not have a contract for delivering this at Humshaugh & Wark Medical Group. As soon as we are in a position to offer the treatment we will update this notice.

To be eligible for the NHS injection a patient must have a BMI ≥40 and 4 out of the following 5 conditions.:

  • Atherosclerotic Cardiovascular Disease – IHD, CVA/TIA, PAD, HF
  • Hypertension – On treatment
  • High Cholesterol – On Lipid Lowering Therapy (or LDL >=4.1 or HDL <1.0 for men or HDL <1.3 women or fasting triglycerides >=1.7)
  • Obstructive Sleep Apnoea (OSA) – Meets criteria for CPAP or equivalent
  • Diabetes Type 2

Phased Primary Care Cohorts (2025–2028)

The programme will develop over the coming years as follows:

  • Cohort I (2025-26 ):  4 or more of the comorbidities listed above and BMI ≥40
  • Cohort II (2026-27):  4 or more comorbidities listed above and BMI 35-39.9
  • Cohort III (2026-2028):  3 or more comorbidities listed above and BMI ≥40

Page last reviewed: 11 July 2025
Page created: 17 April 2025